85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 627 / Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05052229 (ClinicalTrials.gov) | April 21, 2022 | 2/9/2021 | Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF). | Pulmonary Gas Exchange and Neuro-sensory Abnormalities in Patients With Idiopathic Pulmonary Fibrosis and Mild Mechanical Restriction. Implications for Dyspnea and Exercise Intolerance | Idiopathic Pulmonary Fibrosis | Drug: Nitric Oxide;Drug: Medical air | Queen's University | Boehringer Ingelheim | Recruiting | 40 Years | N/A | All | 40 | Early Phase 1 | Canada |
2 | NCT03688334 (ClinicalTrials.gov) | June 1, 2018 | 20/9/2018 | Acute Effects of Oxygen Supplementation Among IPF Patients | Acute Effects of Oxygen Supplementation During Exercise Among Patients With Idiopathic Pulmonary Fibrosis Without Resting Hypoxemia | Idiopathic Pulmonary Fibrosis | Drug: Oxygen 40 %;Drug: Medical air (sham O2) | George Papanicolaou Hospital | NULL | Unknown status | 18 Years | 80 Years | All | 15 | N/A | Greece |